SVNS — Solvonis Therapeutics Share News
0.000.00%
Last trade - 00:00- £17.70m
- £16.06m
- 21
- 11
- 84
- 28
REG - Solvonis Therapeutic - Corporate Structure Update and Issue of Options
AnnouncementREG - Solvonis Therapeutic - Appoints global biopharma leader Paul Carter
AnnouncementREG - Solvonis Therapeutic - Raises £1.25 Million to Accelerate Programmes
AnnouncementREG - Solvonis Therapeutic - Half-year Report
AnnouncementREG - Solvonis Therapeutic - Solvonis secures exclusive CNS collaboration
AnnouncementRCS - Solvonis Therapeutic - Media Coverage: Small Cap Idea profile
AnnouncementREG - Solvonis Therapeutic - SVN-SDN-14 PTSD - Positive pre-clinical results
AnnouncementREG - Solvonis Therapeutic - Total Voting Rights
AnnouncementREG - Solvonis Therapeutic - Translational Bridging Studies
AnnouncementREG - Solvonis Therapeutic - Exercise of warrants
AnnouncementRCS - Solvonis Therapeutic - Solvonis Chair to speak at Lucid Capital Markets
AnnouncementREG - Solvonis Therapeutic - £1m subscription to accelerate AI drug discovery
AnnouncementREG - Solvonis Therapeutic - Holding(s) in Company
AnnouncementREG - Solvonis Therapeutic - AGM Statement
AnnouncementREG - Solvonis Therapeutic - Holding(s) in Company
AnnouncementRCS - Solvonis Therapeutic - Initiation of Research Coverage
AnnouncementREG - Solvonis Therapeutic - Allowance of U.S. patent covering AI-supported CNS
AnnouncementREG - Solvonis Therapeutic - Initiation of AI supported CNS drug discovery
AnnouncementREG - Solvonis Therapeutic - Synthesis of development candidate for SVN-SDN-014
Announcement